Dunn D L
Department of Surgery, University of Minnesota, Minneapolis 55455.
Am J Surg. 1993 Nov;166(5):449-55. doi: 10.1016/s0002-9610(05)81141-9.
The use of biologic reagents directed against invading microbes and deleterious aspects of the host response is presently under intense investigation. The development and use of these reagents have contributed significantly to our understanding of the host response to infection, and they probably represent the first true foray into the area of immunotherapeutic manipulation. Thus, the effects of the administration of anti-endotoxin and antitumor necrosis factor-alpha monoclonal antibodies and the interleukin-1 receptor antagonist are being examined in large-scale clinical trials, and tumor necrosis factor-binding protein and bactericidal/permeability-increasing protein also may undergo clinical testing. Much controversy has already arisen regarding the manner in which these therapeutic reagents will be best utilized. The enormous amount of information that has already been obtained concerning the use of these reagents assuredly will contribute significantly to our understanding of the diagnosis and treatment of serious infection and will set the stage for the development and appropriate testing of additional new diagnostic and therapeutic reagents during the current decade.
目前，针对入侵微生物以及宿主反应有害方面的生物试剂的应用正在深入研究中。这些试剂的研发和使用极大地促进了我们对宿主感染反应的理解，它们可能代表了免疫治疗操作领域的首次真正尝试。因此，抗内毒素和抗肿瘤坏死因子-α单克隆抗体以及白细胞介素-1受体拮抗剂的给药效果正在大规模临床试验中进行研究，肿瘤坏死因子结合蛋白和杀菌/通透性增加蛋白也可能会进行临床试验。关于如何最佳利用这些治疗试剂已经引发了诸多争议。关于这些试剂使用所获得的大量信息无疑将极大地促进我们对严重感染诊断和治疗的理解，并为当前十年中额外新型诊断和治疗试剂的研发及适当测试奠定基础。
